Under the expanded FDA label, up to 1.8 million individuals in the United States could be eligible for sacubitril/valsartan, and up to 180,000 worsening heart failure (HF) events could be prevented or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback